Skip to content
MarketScale
‹ Back to IndustriesSciences

Introducing Marc Coenen as the Fiberguide European Account Manager

Fiberguide recently expanded our footprint to better serve our European customers. Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network. Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction. Marc has a Master of Science degree in Information Technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Promoted Content
Share
Introducing Marc Coenen as the Fiberguide European Account Manager

Key takeaways

01

Fiberguide recently expanded our footprint to better serve our European customers.

02

Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network.

03

Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction.

Fiberguide recently expanded our footprint to better serve our European customers. Marc Coenen, the first Europe-based Fiberguide employee, will support the company’s European distribution network. Fiberguide is working to expand our worldwide footprint, and this exciting new hire is a big step in that direction.

Marc has a Master of Science degree in Information Technology from the University of Technology Eindhoven in the Netherlands. Prior to joining Fiberguide, he served as Sales Manager Automotive Europe, Area Sales Manager, and Application Engineer at Therm-O-Disc. While all of this experience is undoubtedly important, it’s his belief that “If people like you, they’ll listen to you, but if they trust you they’ll do business with you” that certainly sets Marc Coenen apart from the crowd. It is also in line with Fiberguide’s core values of innovative design, outstanding customer service and unparalleled quality.

“After 12 years at my former company, I was looking for a new challenge in a different field,” Marc explains. “A job where I could learn again, pioneer, and bring added value to the company. Fiberguide offered me that unique position to set up the European sales locally.”

Marc’s goal is to expand Fiberguide’s footprint on the European Fiber Optics map—he’ll be working to grow the Fiberguide business significantly by discovering new accounts and working with our EU partner AMS Technologies. “As distributors sell products from several suppliers, they need to know they will have the support and backing of their vendors,” Marc says. “In my role, I will support them in order to get the inquiries awarded and ensure they have the tools needed to succeed.”

If determination is the secret to success, Fiberguide is poised to enjoy a whole new era of growth in Europe thanks to our new European Account Manager’s focus and skills. If you’d like to connect with Marc to learn more about Fiberguide’s operations in Europe, give him a call at +316 1818 5008 or reach out to him at mcoenen@fiberguide.com.

Read more at fiberguide.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512